(Q37073426)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Drug safety in Crohn's disease therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

4

Christian Mottet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

5

Florian Froehlich

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

8

Pierre Michetti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1

Pascal Juillerat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

3

Christian Felley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

6

John-Paul Vader

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

7

Jean-Jacques Gonvers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

161-168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239408%20AND%20SRC:MED&resulttype=core&format=json

Drug safety in the treatment of Crohn's disease

2 January 2020

cites work

1 reference

Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

21 January 2018

1 reference

Antimicrobials in the management of inflammatory bowel disease

21 January 2018

1 reference

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

21 January 2018

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance

21 January 2018

1 reference

Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease

21 January 2018

1 reference

Systematic review: agranulocytosis induced by nonchemotherapy drugs

21 January 2018

1 reference

Review article: monitoring for drug side-effects in inflammatory bowel disease

21 January 2018

1 reference

Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease

21 January 2018

1 reference

No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases

21 January 2018

1 reference

Incidence of sulphasalazine-induced male infertility

21 January 2018

1 reference

Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France

21 January 2018

1 reference

Treatment of inflammatory bowel disease: safety and tolerability issues

21 January 2018

1 reference

Comparative tolerability of treatments for inflammatory bowel disease

21 January 2018

1 reference

Incidence of Clostridium difficile infection in inflammatory bowel disease.

21 January 2018

1 reference

Review article: the limitations of corticosteroid therapy in Crohn's disease

21 January 2018

1 reference

Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety

21 January 2018

1 reference

Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety

21 January 2018

1 reference

Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients

21 January 2018

1 reference

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

The efficacy of methotrexate for maintaining remission in inflammatory bowel disease

21 January 2018

1 reference

Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease

21 January 2018

1 reference

Methotrexate and histologic hepatic abnormalities: a meta-analysis

21 January 2018

1 reference

Methotrexate: first-line or second-line immunomodulator?

21 January 2018

1 reference

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

Review article: safety of infliximab in clinical trials

21 January 2018

1 reference

Infusion reactions and their management

21 January 2018

1 reference

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

21 January 2018

1 reference

Risks and benefits of biologic therapy for inflammatory bowel diseases

21 January 2018

1 reference

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

21 January 2018

1 reference

Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease

21 January 2018

1 reference

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

21 January 2018

1 reference

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

Certolizumab pegol: in Crohn's disease

21 January 2018

1 reference

Ciclosporin and refractory colitis

21 January 2018

1 reference

Tacrolimus: a further update of its use in the management of organ transplantation

21 January 2018

1 reference

Alternative immunomodulators

21 January 2018

1 reference

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up

21 January 2018

1 reference

Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome

21 January 2018

1 reference

Natalizumab for active Crohn's disease

21 January 2018

1 reference

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference